191 related articles for article (PubMed ID: 37200263)
1. Exploring biomarkers and prognostic factors in uterine carcinosarcoma: An insight into L1CAM, CDX2, p53, and MSI status.
da Silva JL; de Albuquerque LZ; Rodrigues FR; Bastos NC; Small IA; Barroso EBC; Cordero FL; Fernandes DS; Paulino E; de Melo AC
PLoS One; 2023; 18(5):e0285447. PubMed ID: 37200263
[TBL] [Abstract][Full Text] [Related]
2. The prevalence and prognostic impact of tumor-infiltrating lymphocytes in uterine carcinosarcoma.
da Silva JL; de Albuquerque LZ; Rodrigues FR; de Mesquita GG; Chaves CBP; Bonamino MH; de Melo AC
BMC Cancer; 2021 Dec; 21(1):1306. PubMed ID: 34876047
[TBL] [Abstract][Full Text] [Related]
3. L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelial-mesenchymal transition.
Versluis M; Plat A; de Bruyn M; Matias-Guiu X; Trovic J; Krakstad C; Nijman HW; Bosse T; de Bock GH; Hollema H
Virchows Arch; 2018 Nov; 473(5):591-598. PubMed ID: 30140948
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
[TBL] [Abstract][Full Text] [Related]
5. [Clinicopathological and gene mutation characteristics of uterine carcinosarcoma].
Tu J; Xu JZ; Zhang YS; Deng LF
Zhonghua Yi Xue Za Zhi; 2023 Jun; 103(24):1864-1867. PubMed ID: 37357193
[TBL] [Abstract][Full Text] [Related]
6. Nestin: A biomarker of aggressive uterine cancers.
Hope ER; Mhawech-Fauceglia P; Pejovic T; Zahn CM; Wang G; Conrads TP; Larry Maxwell G; Hamilton CA; Darcy KM; Syed V
Gynecol Oncol; 2016 Mar; 140(3):503-11. PubMed ID: 26718725
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer.
Kim J; Kim SI; Kim NR; Kim H; Kim HS; Chung HH; Kim JW; Lee C; Lee M
Gynecol Oncol; 2023 Jul; 174():231-238. PubMed ID: 37236032
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of the TCGA molecular classification in uterine carcinosarcoma.
Travaglino A; Raffone A; Raimondo D; Arciuolo D; Angelico G; Valente M; Scaglione G; D'alessandris N; Casadio P; Inzani F; Mollo A; Santoro A; Seracchioli R; Franco Zannoni G
Int J Gynaecol Obstet; 2022 Jul; 158(1):13-20. PubMed ID: 34536971
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients.
Iwasa Y; Haga H; Konishi I; Kobashi Y; Higuchi K; Katsuyama E; Minamiguchi S; Yamabe H
Cancer; 1998 Feb; 82(3):512-9. PubMed ID: 9452269
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
Zhu J; Wen H; Bi R; Wu X
J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
[TBL] [Abstract][Full Text] [Related]
11. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna.
Dandamudi RK; Aslam S; Walji N; El-Modir A; Fernando I
Anticancer Res; 2015 Sep; 35(9):4841-7. PubMed ID: 26254376
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of EZH2, p16 and p53 expression in uterine carcinosarcomas.
Makk E; Bohonyi N; Oszter A; Éles K; Tornóczky T; Tóth A; Kálmán E; Kovács K
Pathol Oncol Res; 2023; 29():1611547. PubMed ID: 38146588
[No Abstract] [Full Text] [Related]
14. Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity.
Matsuzaki S; Klar M; Matsuzaki S; Roman LD; Sood AK; Matsuo K
Gynecol Oncol; 2021 Feb; 160(2):586-601. PubMed ID: 33183764
[TBL] [Abstract][Full Text] [Related]
15. Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma.
Saito A; Nishikawa T; Yoshida H; Mizoguchi C; Kitadai R; Yamamoto K; Yazaki S; Kojima Y; Ishikawa M; Kato T; Yonemori K
Gynecol Oncol; 2023 Sep; 176():115-121. PubMed ID: 37506533
[TBL] [Abstract][Full Text] [Related]
16. OSucs: An Online Prognostic Biomarker Analysis Tool for Uterine Carcinosarcoma.
An Y; Wang Q; Sun F; Zhang G; Wang F; Zhang L; Li Y; Ren W; Zhu W; Li Y; Ji S; Guo X
Genes (Basel); 2020 Sep; 11(9):. PubMed ID: 32899312
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases.
Ariyoshi K; Kawauchi S; Kaku T; Nakano H; Tsuneyoshi M
Histopathology; 2000 Nov; 37(5):427-36. PubMed ID: 11119124
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic carcinosarcoma with the same KRAS gene mutation in both carcinomatous and sarcomatous components: molecular evidence for monoclonal origin of the tumour.
Bai Q; Zhang X; Zhu X; Wang L; Huang D; Cai X; Zhou X; Wang J; Sheng W
Histopathology; 2016 Sep; 69(3):393-405. PubMed ID: 27307095
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma.
Van Arsdale AR; Arend RC; Cossio MJ; Erickson BK; Wang Y; Doo DW; Leath CA; Goldberg GL; Huang GS
Cancer Med; 2018 Mar; 7(3):616-625. PubMed ID: 29455465
[TBL] [Abstract][Full Text] [Related]
20. L1 cell adhesion molecule overexpression in hepatocellular carcinoma associates with advanced tumor progression and poor patient survival.
Guo X; Xiong L; Zou L; Sun T; Zhang J; Li H; Peng R; Zhao J
Diagn Pathol; 2012 Aug; 7():96. PubMed ID: 22888955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
